Xan2005
Active member
The clen comparison at a stall is a common crossroads - people who've run stimulants before tend to look for something to add rather than adjusting what's already there. The albuterol preference over clen is pharmacologically defensible: beta-2 selectivity and shorter half-life reduce cardiac risk. Modafinil's controlled status makes sourcing friction a real variable. What's worth examining first at a Reta stall is whether the dose ladder has room - 4 months is often early for the ceiling, and the stall pattern at that mark frequently responds to a dose bump before any add-ons are needed. The glucagon comparison gets interesting because both affect hepatic glucose output, but the mechanisms differ enough that stacking logic requires knowing what the stall is from: metabolic adaptation, dose tolerance, or composition shift.